drugset / Trial / NCT00976534

Study to Evaluate Efficacy, Safety, Tolerability and Pharmacokinetics of AZD1386 in Patients With Peripheral Neuropathic Pain

NCT00976534

Phase 2 Terminated 90 enrolled AstraZeneca
RandomizedParallel-groupTriple-blindTreatment

Summary

The primary aim of this study is to investigate if AZD1386 is efficacious as an analgesic in patients with peripheral neuropathic pain. This will be done by comparing the effect of AZD1386 to placebo ("inactive substance") on pain.

Timeline

Start
2009-09
Primary completion
Completion
2010-02

Drugs

EvaluationDrugModalityDoseRoute
Subject AZD1386 Small molecule 90 mg Oral

Indications